©2026 Incunabulum LLC. All rights reserved. mg Magazine is a registered trademark of Incunabulum LLC. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with prior written permission.
Tag: David Pidduck
MediPharm Labs Reports Fourth Quarter and Full Year 2023 Results
TORONTO - MediPharm Labs Corp., a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended...
MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority
TORONTO - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, received GMP certification for their Barrie, Ontario facility...
MediPharm Labs Reports Third Quarter Results
TORONTO - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the...
MediPharm Labs Settles an Outstanding Claim for $9M
TORONTO -
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a company specialized in precision-based cannabinoids, is pleased...
MediPharm Labs Provides Update on VIVO Integration and Board Appointee
BARRIE, Ontario - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs", "MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids,...
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
TORONTO -
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased...